Welcome, everybody, to the Standing Committee on Industry, Science and Technology, as we pursue our study of the impacts of Canada's regulatory structure on small business. We have a full panel with us today, so I will be tight with my time.
From Pharmascience, we have David Goodman, Chief Executive Officer and Alain Boisvert, Head of Government Affairs and Market Access. From Consumer Health Products Canada, we have Karen Proud, President and Adam Gibson, Vice-President of Public Affairs. From MEDEC, we have Brian Lewis, President and Chief Executive Officer and Diana Johnson, Vice-President of Regulatory Affairs. From the Chemistry Industry Association of Canada, we have Bob Masterson, President and Chief Executive Officer. Thank you all very much for coming.
Each group will have seven minutes to present and then we will go into our rounds of questions for the remainder of the two hours.
Why don't we start with Pharmascience, Mr. Goodman?